Bain Capital Public Equity Management II’s Immunocore IMCR Stock Holding History

Bain Capital Public Equity Management II’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-249,318	Closed	-$9.3M	–	46
2022 Q2	$9.3M	Sell	249,318 -68,358	-22%	-$2.22M	0.46%	33
2022 Q1	$9.5M	Sell	317,676 -394,275	-55%	-$9.95M	0.3%	37
2021 Q4	$24.4M	Buy	711,951 +73,746	+12%	+$2.67M	0.81%	29
2021 Q3	$23.7M	Buy	638,205 +163,651	+34%	+$5.52M	0.83%	31
2021 Q2	$18.5M	Buy	474,554 +173,683	+58%	+$6.7M	0.79%	28
2021 Q1	$12.8M	Buy	+300,871	New	+$13.4M	0.53%	32

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bain Capital Public Equity Management II's IMCR Position: Q3 2022 in Review

Bain Capital Public Equity Management II sold out of Immunocore (IMCR) in Q3 2022, closing a stake of 249,318 shares — an estimated $9.3M sold.

Bain Capital Public Equity Management II first reported a position in IMCR in Q1 2021 and held it in 6 quarters. The position peaked at $24.4M in Q4 2021. 86 funds tracked by Wall St. Rank hold IMCR as of Q3 2022.

Bain Capital Public Equity Management II reported no remaining Immunocore position as of Q3 2022 after selling out during the quarter.
Bain Capital Public Equity Management II sold 249,318 Immunocore shares in Q3 2022, an estimated $9.3M.
Bain Capital Public Equity Management II first reported a position in Immunocore in Q1 2021 and held it in 6 quarters.
Bain Capital Public Equity Management II's Immunocore position peaked at $24.4M in Q4 2021.
86 funds tracked by Wall St. Rank held Immunocore as of Q3 2022.

Based on Bain Capital Public Equity Management II's 13F filing for Q3 2022, filed 14 Nov 2022.